AMF Tjanstepension AB trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 11.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,856 shares of the company's stock after selling 12,520 shares during the period. AMF Tjanstepension AB's holdings in Zoetis were worth $15,295,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Coppell Advisory Solutions LLC raised its stake in Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after purchasing an additional 64 shares during the period. Lindbrook Capital LLC lifted its holdings in Zoetis by 1.8% during the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after buying an additional 65 shares in the last quarter. Legacy Financial Advisors Inc. lifted its holdings in Zoetis by 5.8% during the 4th quarter. Legacy Financial Advisors Inc. now owns 1,282 shares of the company's stock worth $209,000 after buying an additional 70 shares in the last quarter. Quotient Wealth Partners LLC lifted its holdings in Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after buying an additional 72 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. lifted its holdings in Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after buying an additional 73 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.18% of the company's stock.
Zoetis Stock Down 0.6%
Shares of ZTS stock traded down $0.90 on Friday, hitting $147.34. The stock had a trading volume of 2,062,093 shares, compared to its average volume of 3,804,772. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market capitalization of $65.30 billion, a price-to-earnings ratio of 25.36, a P/E/G ratio of 2.41 and a beta of 0.88. The stock's 50 day moving average is $156.71 and its 200-day moving average is $159.76.
Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.56 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.
Zoetis Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is presently 34.42%.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ZTS. Piper Sandler boosted their price objective on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $204.63.
Get Our Latest Report on ZTS
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories

Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.